Drs. Reed and Schulman have served as consultants for Novartis.
Version of Record online: 18 OCT 2004
Copyright © 2004 American Cancer Society
Volume 101, Issue 11, pages 2584–2592, 1 December 2004
How to Cite
Anstrom, K. J., Reed, S. D., Allen, A. S., Glendenning, G. A. and Schulman, K. A. (2004), Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 101: 2584–2592. doi: 10.1002/cncr.20674
Portions of this work were presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31–June 3, 2003, Chicago, Illinois.
See accompanying article on pages 2574–83, this issue.
- Issue online: 16 NOV 2004
- Version of Record online: 18 OCT 2004
- Manuscript Accepted: 20 AUG 2004
- Manuscript Revised: 18 AUG 2004
- Manuscript Received: 15 JUN 2004
- Duke University Medical Center
- Novartis Pharmaceuticals Corporation, East Hanover, NJ
- clinical trials;
- cost-benefit analysis;
- chronic myeloid leukemia;
- survival analysis
The authors estimated survival among patients with chronic myeloid leukemia for a cost-effectiveness analysis of imatinib versus interferon-α plus low-dose cytarabine (IFN+LDAC).
Two-year survival and cytogenetic response were determined using data from 553 patients who received first-line imatinib in the International Randomized Interferon versus ST571 Study (IRIS). Long-term survival was modeled on complete cytogenetic response (CCyR) after 2 years. Long-term survival for patients with a CCyR was modeled using data from a cohort study of 317 patients with CCyRs. Long-term survival for patients without a CCyR was modeled using data from a trial of 275 patients who were treated with IFN+LDAC. Computation of lifetime survival estimates for imatinib assumed a proportional hazards relation between survival for an age-matched and gender-matched cohort and survival for patients with and without a CCyR.
For IRIS patients receiving imatinib, the estimated survival was 95.8% and the CCyR rate was 73.8%. The average residual life expectancy was estimated to be 16.71 years for CCyR patients and 5.78 years for non-CCyR patients. The estimated life expectancy after treatment with imatinib was 15.30 years, compared with 9.07 years for patients who were treated with IFN+LDAC in previous studies.
Assuming the relation between CCyR and survival with interferon-α holds for imatinib, higher CCyR rates with imatinib therapy will result in an estimated 6.23 life-years gained compared with treatment with IFN+LDAC. Cancer 2004. © 2004 American Cancer Society.